Ado.Ax
ADO.AX is a healthcare diagnostics company that develops and commercializes diagnostic tests and related technologies, primarily generating revenue through product sales and research collaborations.
Business. ADO.AX is a healthcare diagnostics company that develops and commercializes diagnostic tests and related technologies, primarily generating revenue through product sales and research collaborations.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ADO.AX is a healthcare diagnostics company that develops and commercializes diagnostic tests and related technologies, primarily generating revenue through product sales and research collaborations.
The company's capital structure is characterized by a debt-to-equity ratio of 0.62, indicating a moderate reliance on debt financing. Liquidity is assessed as medium, with a current ratio of 2.08, suggesting the company has sufficient short-term assets to cover its short-term liabilities, but with limited excess capacity for operational flexibility. The negative net cash position after subtracting total debt highlights a potential liquidity constraint, particularly in the context of ongoing operating losses.
Profitability metrics are weak, with a return on equity of -2.1456 and a return on assets of -1.0484, both significantly below the industry median for biotechnology and medical research firms. These figures indicate that the company is not generating returns that meet the cost of equity or asset base, which is a red flag for investors.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare diagnostics sector, where regulatory and reimbursement changes can significantly impact revenue streams.
Growth trajectory is negative, with the company reporting a revenue of 1,027,710 AUD in the latest period. The operating and net losses of -9,190,150 AUD and -6,759,140 AUD, respectively, suggest that the company is not yet achieving profitability. The outlook for the current and next fiscal years is not provided, but the continued negative operating cash flow of -5,826,190 AUD and free cash flow of -5,856,080 AUD indicate ongoing financial strain.
Risk factors include a high probability of liquidity constraints due to the negative net cash position and ongoing operating losses. The dilution potential is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. However, the company's negative cash flows and high debt levels may necessitate future equity or debt financing, which could lead to dilution.
Recent events include the latest financial filing, which discloses the company's continued losses and negative cash flows. No recent earnings call transcripts or material events are available to provide additional context on the company's strategic direction or operational performance.
- ADO.AX is a healthcare diagnostics company with a weak profitability profile, as evidenced by negative returns on equity and assets.
- The company's liquidity position is medium, with a current ratio of 2.08, but a negative net cash position after debt.
- Revenue is concentrated in a single segment, with no geographic diversification disclosed, increasing exposure to market-specific risks.
- The company is not yet profitable, with significant operating and net losses, and negative operating and free cash flows.
- The risk of liquidity constraints is high, and the company may need to raise additional capital in the future, which could lead to dilution.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ADO.AX Market data — financials · 2026-05-27